- Home
- NDLS vs KALA Comparison
NDLS vs KALA Comparison
Compare NDLS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- KALA
- Stock Information
- Founded
- NDLS 1995
- KALA 2009
- Country
- NDLS United States
- KALA United States
- Employees
- NDLS N/A
- KALA N/A
- Industry
- NDLS Restaurants
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- KALA Health Care
- Exchange
- NDLS Nasdaq
- KALA Nasdaq
- Market Cap
- NDLS 32.9M
- KALA 26.2M
- IPO Year
- NDLS 2013
- KALA 2017
- Fundamental
- Price
- NDLS $0.87
- KALA $6.08
- Analyst Decision
- NDLS Strong Buy
- KALA Strong Buy
- Analyst Count
- NDLS 2
- KALA 3
- Target Price
- NDLS $3.00
- KALA $14.00
- AVG Volume (30 Days)
- NDLS 224.2K
- KALA 133.6K
- Earning Date
- NDLS 08-06-2025
- KALA 08-05-2025
- Dividend Yield
- NDLS N/A
- KALA N/A
- EPS Growth
- NDLS N/A
- KALA N/A
- EPS
- NDLS N/A
- KALA N/A
- Revenue
- NDLS $495,670,000.00
- KALA N/A
- Revenue This Year
- NDLS $5.37
- KALA N/A
- Revenue Next Year
- NDLS $0.68
- KALA N/A
- P/E Ratio
- NDLS N/A
- KALA N/A
- Revenue Growth
- NDLS N/A
- KALA N/A
- 52 Week Low
- NDLS $0.55
- KALA $2.92
- 52 Week High
- NDLS $1.83
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- NDLS 57.51
- KALA 58.29
- Support Level
- NDLS $0.80
- KALA $5.39
- Resistance Level
- NDLS $0.82
- KALA $7.00
- Average True Range (ATR)
- NDLS 0.09
- KALA 0.71
- MACD
- NDLS 0.02
- KALA 0.04
- Stochastic Oscillator
- NDLS 87.57
- KALA 51.89
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.